Our Team
Our deep scientific, investment and operational expertise in the pharmaceutical industry allows us to identify profitable investment opportunities and support the management team of our portfolio companies to achieve their goal of improving healthcare.
We also have access to the Pharmascience Group’s extensive network of experts in the development, manufacturing, and marketing of medicines.
Management Team
Growth and Success
Dr. David Goodman is Executive Chairman of the Board of Pharmascience Inc., after serving as CEO of the company from 2006 to 2022. Prior to this nomination, he was Executive Vice President of Pharmascience International. He started his career at Pharmascience in Business Development before taking successively senior domestic and international roles. His business acumen, leadership skills and innovative vision have allowed Pharmascience to expand into a tier-1 Canadian pharmaceutical company with both branded and generic products, including significant international operations in growth regions. His focus on investing in R&D programs, fostering a culture of continuous innovation and meeting customers’ needs, have been pillars of his leadership.
Innovator and Entrepreneur
Dr. Goodman is involved in innovation inside and outside Pharmascience. He currently serves as a board member on several private companies such as Bion Pharma (Princeton, NJ) and is involved in many entrepreneurial activities. He also served as an advisor to a number of private equity funds.
Dr. Goodman holds a bachelor’s degree of Commerce from McGill University and a Ph.D. in Pharmacology from the University of Virginia.
Continuing the Philanthropic Legacy
Dr. Goodman continues the company’s strong philanthropic legacy with Centraide, and other organizations which the company supports through various employee and industry initiatives. He serves on the boards of the Rosalind and Morris Goodman Cancer Institute at McGill University, Centraide of Greater Montreal, as well as the President’s Advisory Committee for the Jewish General Hospital Board of Directors.
Pierre Beauparlant, Ph.D, has more than 25 years of experience in large pharma and development stage, venture backed biopharmaceutical companies. Throughout his career, Dr. Beauparlant has demonstrated exceptional skills in the creation, financing, and management of early-stage companies with a mission to develop new therapies. His strategic insights and business acumen have played a pivotal role in advancing numerous innovative projects and bringing them to market.
Prior to joining Finchley Healthcare Ventures, he was venture partner at Sanderling Ventures, one of the earliest life-science venture capital funds of the San Francisco Bay area and served as CEO of several portfolio companies, including PreciThera Inc. an early-stage company specialized in developing biologics for rare musculoskeletal diseases and SpecificiT Pharma Inc. a clinical stage company developing cellular therapies for cancer. Previously, he served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Dr. Beauparlant oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities. Prior to Novartis, he held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property.
Dr. Beauparlant holds a Ph.D. from McGill University in microbiology and immunology. He was awarded a Canadian Medical Research scholarship and was named to the Dean’s Honor List.
Gabrielle Bertier joined Finchley Healthcare Ventures as a Senior Analyst to help evaluate emerging therapeutic innovations and their potential impact on healthcare.
Prior to joining Finchley in 2023, she was Health Policy and Reimbursement Manager at Imagia Canexia Health, and led patient access and reimbursement strategy for oncology genomic assays. Dr. Bertier has over a decade of experience in healthcare across Europe, Canada and the US in both academia and industry. She has orchestrated numerous life science collaborations and partnerships, including fundamental research projects, clinical trials, and multicentric alliances, across a variety of therapeutic areas.
Dr. Bertier earned her Ph.D. in Human Genetics from McGill University, completing her doctoral work through a co-tutelle with Toulouse III Paul Sabatier University in France, where she obtained her Doctorate in Biology, Health, and Biotechnologies, with a specialization in Bioethics. She holds a Master’s degree in international affairs from Sciences-Po Paris and a Bachelor’s degree in biology from Pierre and Marie Curie University in Paris.
Camille Couture, Ph.D., joined Finchley Healthcare Ventures in 2024 as an Investment Analyst. In her role, she supports the evaluation of novel therapeutic innovations and assesses their potential impact on healthcare.
Prior to joining Finchley, Dr. Couture completed several prestigious training programs, including the Private Capital Governance program by the Canadian Venture Capital and Private Equity Association and the Quebec Science Entrepreneurship program. These experiences have equipped her with a comprehensive understanding of the intersection between clinical research, entrepreneurship, and private equity. Additionally, she served as the Programming Chair for the Greater-Montreal Women in Bio chapter for six years, where she coordinated events focused on scientific trends and venture capital.
Dr. Couture holds a Ph.D. in Microbiology and Immunology from the Université de Montréal, where she was named to the Dean’s Honour List and completed a six-month internship at the Mayo Clinic Graduate School of Biomedical Sciences. She also earned a master’s degree in Neuroscience and a bachelor’s degree in Anatomy and Cell Biology from McGill University, providing her with a broad expertise in the life sciences.
Mr. Caron oversees the finance and administrative aspects of Finchley Healthcare Ventures, supporting valuation and investment processes. Before joining Finchley in 2023, he held various finance roles at Pharmascience, starting as a Senior Financial Analyst for Treasury in 2017 and becoming Plant Controller for the Candiac site in 2018. There, he gained expertise in injectables and OSD production and was the finance lead for the Candiac sterile facility expansion. He later served as Manager of Financial Planning and Analysis for the company.
Prior to Pharmascience, Mr. Caron was Director of Administration and Finance at Solmax Chile in Santiago and worked in Corporate Finance at Agropur, one of the world’s largest dairy cooperatives.
He holds an M.Sc. from HEC Montreal, where his thesis on Syndicated Lending in Canada during the 2007-2008 financial crisis was among the best of his cohort. He graduated cum laude from the John Molson School of Business at Concordia University with a Bachelor of Commerce degree and is also a CFA charterholder.
Ms. Verner joined the Finchley Healthcare Ventures team in 2022 as an executive assistant. She provides administrative support for David and Morris Goodman, as well as for Pierre Beauparlant.
Ms. Verner has a degree in secretarial sciences. Her career began over 35 years ago, and she spent most of it in the aeronautical sector as an administrative assistant, before turning to the exciting world of pharmaceuticals. For nearly 18 years, she assisted various managers at Bombardier Aerospace, before joining the Pharmascience team as the CEO’s assistant.
Board of Directors
Mr. Wasserstein currently is and has been since 2012 a Senior Investment Banker at Greenhill & Co., regularly advising Boards and Senior Managements in the biotechnology, specialty pharmaceuticals and generics space on complex transactions and business issues. He also has an over 20-year track record as a transformational pharma industry leader with strong P&L and administrative experience building, fixing, and growing diverse pharma businesses and organizations.
Over his career, he has held senior management roles at Fougera Pharmaceuticals, Dr. Reddy’s Laboratories (as Executive Vice President, North America Operations, a member of the Global Executive Management Council, and Founder and President of Promius Pharma, the Company’s Specialty Pharma Operations) and Avigenics, Inc. (rebranded as Synageva Biopharma) an early-stage biotechnology company developing therapeutic proteins.
Over a 13-year career at Schering-Plough, M. Wassertein served in various senior leadership positions, including Senior Vice President reporting directly to two Chairmen and CEO (Fred Hassan and Richard Kogan), President & GM of Schering-Plough Canada, Head of Corporate Business Development, Strategic Planning and Chief of Staff to the Operating Committee of the parent company and Associate General Counsel and Chief Counsel for both Global Pharmaceutical Operations and Consumer Healthcare Products.
Ildiko Mehes is a pharmaceutical industry board member, advisor, and former executive with over 20 years’ experience driving value creation, risk mitigation, and transformation, in both large global public companies and privately held, branded, specialty and generic companies. Ms. Mehes also currently advises investment management firms, hedge funds, VCs, and consulting firms about a broad range of risks and opportunities in the pharmaceutical industry, including M&A, drug portfolios, litigation, FDA regulatory and quality issues and more.
Ms. Mehes began her career in 2000 as a pharmaceutical patent and commercial litigator at a preeminent Toronto law firm, Goodmans LLP. She joined Teva Pharmaceuticals in 2005 and was successively promoted by multiple CEOs in dual legal and business roles over 12 years, including SVP & General Counsel, Global Generic Medicines (serving on both the global and North American Executive Management Teams and the global Biosimilars Committee), VP & Leader, U.S. New Product & Portfolio (chairing the cross-functional Long-Range Strategy Committee), and General Counsel & VP Scientific Affairs (serving on the Executive Management Team in Canada).
Ms. Mehes is the recipient of several Canadian and global awards, including the Global Counsel Award (individual) from the Association of Corporate Counsel, the Canadian General Counsel Award for litigation management, Milestone Case of the Year awards, and recognition as a Corporate IP All-Star by Managing Intellectual Property magazine.
Ms. Mehes completed Wharton Business School’s flagship executive education program, the Advanced Management Program.
Growth and Success
Dr. David Goodman is Executive Chairman of the Board of Pharmascience Inc. after serving as CEO of the company from 2006 to 2022. Prior to this nomination, he was Executive Vice President of Pharmascience International. He started his career at Pharmascience in Business Development before taking successively senior domestic and international roles. His business acumen, leadership skills and innovative vision have allowed Pharmascience to expand into a tier-1 Canadian pharmaceutical company with both branded and generic products, including significant international operations in growth regions. His focus on investing in R&D programs, fostering a culture of continuous innovation and meeting customers’ needs, have been pillars of his leadership.
Innovator and Entrepreneur
Dr. Goodman is involved in innovation inside and outside Pharmascience. He currently serves as a board member on several private companies such as Bion Pharma (Princeton, NJ) and is involved in many entrepreneurial activities. He also served as an advisor to a number of private equity funds.
Dr. Goodman holds a bachelor’s degree of Commerce from McGill University and a Ph.D. in Pharmacology from the University of Virginia.
Continuing the Philanthropic Legacy
Dr. Goodman continues the Pharmascience’s strong philanthropic legacy with Centraide, and other organizations which the company supports through various employee and industry initiatives. He serves on the boards of the Rosalind and Morris Goodman Cancer Institute at McGill University, Centraide of Greater Montreal, as well as the President’s Advisory Committee for the Jewish General Hospital Board of Directors.
Co-Founder & Chairman Emeritus
As a pioneer and leading entrepreneur in the Canadian generic drug industry, Mr. Morris Goodman has dedicated his career to creating a difference in global healthcare.
After graduating from the University of Montreal’s Faculty of Pharmacy in 1953, Mr. Goodman co-founded his first company, Winley-Morris. In 1971, he sold Winley-Morris to the International Chemical & Nuclear Corporation (ICN) and continued to serve as the President of ICN Canada until 1983.
A Leader and a Visionary
With a determination to transform the Canadian pharmaceutical industry through innovation and R&D, Mr. Goodman co-founded Pharmascience in 1983 with trusted friend and fellow pharmacist Ted Wise. Mr. Goodman’s leadership and vision piloted Pharmascience to the forefront of this industry to become one of the top generic pharmaceutical manufacturers in Canada.
A Passionate Philanthropist
Mr. Goodman is a passionate philanthropist, devotedly giving back to the community through The Morris & Rosalind Goodman Family Foundation, notably with The Stroke Unit at the Jewish General Hospital of Montreal, the Faculty of Pharmacy and Outremont Campus at the University of Montreal, CHU Sainte-Justine’s Goodman Pediatric Formulations Centre, and The Rosalind & Morris Goodman Cancer Research Centre at McGill University.
about the team?